

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[About Cancer & Treatment](#)

[About Cancer & Treatment](#)

What can we help you find today?

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA

Our experts can help determine which clinical trial is right for you. Browse our listing of clinical trials that are currently enrolling new patients.



Physician-scientist Ping Chi develops clinical trials to personalize treatment for people with sarcoma.

Search by keywords:

and/or

Trial phase:

19 Clinical Trials found

[A Phase 1 Study of DCC-3009 in People With Advanced Gastrointestinal Stromal Tumors](#)

Researchers want to find the best dose of DCC-3009 to use in people with gastrointestinal stromal tumors (GIST). The people in this study have GIST that has metastasized (spread) after treatment. In addition, their cancers have a mutation (change) in the KIT or PDGFRA gene. These mutations are common in people with GIST and can cause cancer to grow.

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[A Phase 1 Study of DS-2243a in People With Advanced Solid Tumors](#)

Researchers want to find the best dose of DS-2243a to use in people with solid tumors. The people in this study have these solid tumors, which have spread beyond their original location:

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[A Phase 1 Study of IMA203 Cellular Therapy With mRNA-4203 in People With Cutaneous Melanoma or Synovial Sarcoma](#)

Researchers are seeking the best dose of mRNA-4203 to give with a cellular therapy in people with melanoma or sarcoma. The cellular therapy is called IMA203 and is custom-made from each patient's white blood cells.

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[A Phase 1 Study of MQ710 in People With Solid Tumors](#)

In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[A Phase 1 Study of PYX-201 in People With Advanced Solid Tumors](#)

Researchers are evaluating PYX-201 in people with solid tumors that have spread and keep growing after treatment. The people in this study have these cancers:

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[A Phase 1 Study of Ziftomenib Plus Imatinib in People With Advanced Gastrointestinal Stromal Tumors](#)

Researchers want to find the best dose of ziftomenib to give with imatinib in people with advanced gastrointestinal stromal tumors (GIST). The people in this study have GIST that keeps growing after treatment.

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[A Phase 1-2 Study of ADCE-D01 in People With Advanced Soft Tissue Sarcoma](#)

Researchers want to find the best dose of ADCE-D01 to treat soft tissue sarcoma. In this study, we treat people with soft tissue sarcoma that is inoperable (cannot be surgically removed) or metastasized (spread).

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[A Phase 1/2 Study of Afamitresgene Autoleucel SPEAR T Cell Therapy in Children and Young Adults With Solid Tumors](#)

Researchers are assessing a new type of therapy in young people with solid tumors that keep growing even after treatment. The therapy is called afamitresgene autoleucel. The people in this study have synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), neuroblastoma, or osteosarcoma. In addition, they have tested positive for the HLA-A*02 gene and their cancers make a protein called MAGE-A4. This protein plays a role in cancer growth.

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[A Phase 1/2 Study of DCC-3116 Plus Ripretinib for People with Advanced Gastrointestinal Stromal Tumor](#)

Researchers want to find the best dose of DCC-3116 to give with ripretinib for people with gastrointestinal stromal tumor (GIST). The people in this study have GIST that has spread, even with treatment.

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[A Phase 1b/2 Study of Mirdametinib Plus Palbociclib in People With Advanced Dedifferentiated Liposarcoma](#)

Mirdametinib blocks proteins called MEK1 and MEK2, which play an important role in cancer cell growth and survival. By blocking MEK1 and MEK2, mirdametinib may slow or stop the growth of your cancer.

[New York City](#) , [Commack](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

1
2

© 2026 Memorial Sloan Kettering Cancer Center